Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial
carcinoma (UC). Most patients inevitably encounter drug resistance and resultant disease …

Bladder cancer (BCa) is the 9th most common malignant tumor and the 13th leading cause
of death due to cancer. The development of surgery and target drugs bring new challenges …

Background Cisplatin-based chemotherapy is mainstay treatment in urinary bladder cancer
(UBC). However, tumor recurrence frequently occurs with the acquisition of cisplatin …

Therapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is
limited by chemoresistance. To elucidate underlying mechanisms and to develop new …

Background Bladder cancer (BC) is a common malignancy worldwide that accounts for 3%
of global cancer diagnoses. Chemotherapy resistance limits the therapeutic effect of …

Human urinary bladder cancer is the fifth most common cancer in the United States, and the
long-term disease-free survival in patients is still suboptimal with current chemotherapeutic …

Bladder cancer (BCa) is the most vital urogenital malignant disease worldwide, bringing
huge economic and social burden every year. Clinically, BCa is subdivided into superficial …

Paclitaxel (PTX) is commonly used to treat urothelial carcinoma (UC) after platinum-based
chemotherapy has failed. However, single-agent taxane therapy is not sufficient to inhibit …

Cisplatin-based chemotherapy is the first-line therapy for bladder cancer. However, cisplatin
resistance has been associated with the recurrence of bladder cancer. Previous studies …

Repurposing existing drugs for cancer treatment is an effective strategy. An approved
antipsychotic drug, trifluoperazine (TFP), has been reported to have potential anticancer …